Home

Peter Justin Klein

CIK 1608710 · last filed 2021-06-04

Peter Justin Klein is a corporate insider who has filed 26 SEC Form 4 insider transactions across 2 companies since 2016. The most recent filing, for PHAS, was dated Jun 4, 2021. Current disclosed insider exposure totals $184.6K across reported positions. 2 SEC filings were submitted jointly with Kirk G. Nielsen.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$184.6K

Companies

2

Total Filings

26

Lifetime Open-Market Net

$0

Filer Profile

Reported Address
5425 WISCONSIN AVE
CHEVY CHASE, MD 20815
Related Filers
Kirk G. Nielsen — 2 joint filings, latest 2026-02-10
Vensana Capital I, L.P. — 2 joint filings, latest 2026-02-10
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
PhaseBio Pharmaceuticals Inc (PHAS) Delisted Director 2,303 $0.07 $161 $0 5 2021-06-04
SENS Director 18,459 $10.00 $184.6K $0 21 2021-04-05

Recent Filings

26 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2021-06-04 PhaseBio Pharmaceuticals Inc (PHAS) Delisted Grant (A) — $0 EDGAR
2021-04-05 SENS Grant (A) +2,470 $6.4K EDGAR
2021-01-06 SENS Grant (A) +6,853 $6.4K EDGAR
2020-10-05 SENS Grant (A) +16,375 $6.4K EDGAR
2020-08-20 SENS Grant (A) +273,077 $0 EDGAR
2020-07-22 SENS Grant (A) +273,077 $0 EDGAR
2020-07-02 SENS Grant (A) +16,905 $6.4K EDGAR
2020-06-05 PhaseBio Pharmaceuticals Inc (PHAS) Delisted Grant (A) — $0 EDGAR
2020-04-03 SENS Grant (A) +11,184 $6.4K EDGAR
2020-01-06 SENS Grant (A) +6,959 $6.4K EDGAR
Showing 1–10 of 26
Page 1 of 3
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.